NPC 17923

Drug Profile

NPC 17923

Latest Information Update: 16 Jul 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scios
  • Class Aminobenzoic acids; Anti-inflammatories; Antirheumatics; Fluorenes; Small molecules
  • Mechanism of Action Immunosuppressants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 16 Jul 1998 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
  • 16 Jul 1998 No-Development-Reported for Ulcerative colitis in USA (Unknown route)
  • 01 Jun 1995 Rhone-Poulenc Rorer is developing NPC 17923 in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top